Medcaw Investments is seeking suitable acquisitions in the life sciences sector, particularly those companies involved in medical technologies or therapies. Because of the change in rules for the standard list that target must make the enlarged company worth at least £30m when it applies for readmission. Medcaw Investments was able to float, because it had already applied for a listing prior to the change in the rules on 3 December 2021.
The share price ended the day at 10.5p (9p/12p). There...
You are unauthorized to view this page.